A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder.

Trial Profile

A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2017

At a glance

  • Drugs Flibanserin (Primary)
  • Indications Decreased libido
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MAGNOLIA; ORCHID
  • Sponsors Sprout Pharmaceuticals
  • Most Recent Events

    • 16 May 2017 Results of a post-hoc analysis from three 24-week trials presented at the 112th Annual Meeting of the American Urological Association
    • 18 Aug 2015 According to a Sprout Pharmaceuticals media release, the US FDA has approved flibanserin 100 mg (Addyi) for the treatment of acquired generalized hypoactive sexual desire disorder in premenopausal women.
    • 04 Jun 2015 According to a Sprout Pharmaceuticals media release, the FDA advisory committee has recommended for approval flibanserin (ADDYI) for the treatment of hypoactive sexual desire disorder in premenopausal women.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top